e-learning
resources
ERJ
2017
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Acquired resistance to macrolides in
Pseudomonas aeruginosa
from cystic fibrosis patients
Muhammad-Hariri Mustafa, Shaunak Khandekar, Michael M. Tunney, J. Stuart Elborn, Barbara C. Kahl, Olivier Denis, Patrick Plésiat, Hamidou Traore, Paul M. Tulkens, Francis Vanderbist, Françoise Van Bambeke
Source:
Eur Respir J, 49 (5) 1601847; 10.1183/13993003.01847-2016
Journal Issue:
May
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Muhammad-Hariri Mustafa, Shaunak Khandekar, Michael M. Tunney, J. Stuart Elborn, Barbara C. Kahl, Olivier Denis, Patrick Plésiat, Hamidou Traore, Paul M. Tulkens, Francis Vanderbist, Françoise Van Bambeke. Acquired resistance to macrolides in
Pseudomonas aeruginosa
from cystic fibrosis patients. Eur Respir J, 49 (5) 1601847; 10.1183/13993003.01847-2016
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Variability of ß-lactamase resistance Pseudomonas aeruginosa genes infecting patients with cystic fibrosis
Source: Virtual Congress 2021 – Back to infection basics
Year: 2021
Eradication of Pseudomonas aeruginosa in cystic fibrosis patients
Source: Eur Respir J 2006; 27: 653
Year: 2006
Inflammatory markers in cystic fibrosis patients with transmissible Pseudomonas aeruginosa
Source: Eur Respir J 2003; 22: 503-506
Year: 2003
Factors associated with infection by Pseudomonas aeruginosa in adult cystic fibrosis
Source: Eur Respir J 2005; 26: 651-656
Year: 2005
Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis},
Source: Eur Respir J 2012; 40: 1014-1023
Year: 2012
Characterization of the resistance mechanisms to carbapenems and virulence genes in Pseudomonas aeruginosa strains from children with cystic fibrosis.
Source: Virtual Congress 2021 – Cystic fibrosis in children: various aspects
Year: 2021
Eradication of Pseudomonas aeruginosa in cystic fibrosis
Source: Eur Respir J 2006; 27: 438-439
Year: 2006
Epidemiological-molecular study of colonization by pseudomonas aeruginosa in cystic fibrosis patients
Source: Eur Respir J 2002; 20: Suppl. 38, 379s
Year: 2002
Daily versus weekly azithromycin in cystic fibrosis patients
Source: Eur Respir J 2007; 30: 487-495
Year: 2007
Epidemiology of Pseudomonas aeruginosa in a cystic fibrosis rehabilitation centre
Source: Eur Respir J 2005; 25: 474-481
Year: 2005
Antibodies against Pseudomonas aeruginosa in patients with cystic fibrosis – clinical application
Source: International Congress 2018 – Cystic fibrosis in paediatric patients: current research
Year: 2018
Highly concentrated aerosolized tobramycin in the treatment of patients with cystic fibrosis and
Pseudomonas aeruginosa
infection
Source: Eur Respir J 2005; 26: Suppl. 49, 620s
Year: 2005
Omics-based tracking of
Pseudomonas aeruginosa
persistence in “eradicated” cystic fibrosis patients
Source: Eur Respir J, 57 (4) 2000512; 10.1183/13993003.00512-2020
Year: 2021
Increased airway iron as a potential factor in the persistence of Pseudomonas aeruginosa infection in cystic fibrosis
Source: Eur Respir J 2007; 30: 286-292
Year: 2007
Evaluating the Leeds criteria for Pseudomonas aeruginosa infection in a cystic fibrosis centre
Source: Eur Respir J 2006; 27: 937-943
Year: 2006
Azithromycin in chronic respiratory infections with
pseudomonas aeruginosa
in patients without cystic fibrosis
Source: Annual Congress 2008 - Mechanisms of respiratory infections: interaction between the pathogen and the host
Year: 2008
Pseudomonas aeruginosa in the home environment of newly infected cystic fibrosis patients
Source: Eur Respir J 2008; 31: 822-829
Year: 2008
Chronic use of azithromycin in CF is associated with a substantial increase in macrolide resistance of
S. aureus
and
haemophilus
Source: Annual Congress 2006 - Cystic fibrosis lung disease: molecules images and drugs
Year: 2006
Efficacy of ciprofloxacin against resistant mucoid or non-mucoid
P. aeruginosa
isolated from non-cystic fibrosis bronchiectasis (NCFB) patients considering lung pharmacokinetics after ciprofloxacin DPI treatment
Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept